BrainStorm Cell falls on FDA concerns over ALS therapy

Lineage Cell Therapeutics

25/09/2023 13:43

** Shares of biotechnology company Brainstorm Cell
Therapeutics  BCLI.O  down nearly 50% at 44 cents premarket 
    ** Co says FDA staff reviewers raise concerns about its
Amyotrophic Lateral Sclerosis (ALS) therapy
    ** Adds that reviewers found potential issues with quality
and safety of therapy as well as large amounts of missing data
    ** ALS is a neurological disease that affects motor neurons,
which are nerve cells in the brain and spinal cord that control
voluntary muscle movement
    ** Up to last close, BCLI was down 50.26% YTD

 (Reporting by Unnamalai L in Bengaluru)
 ((Unnamalai.L@thomsonreuters.com))